Literature DB >> 19011773

Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts.

Kazutoshi Ikeshita1, Kiyonobu Nishikawa, Sumiko Toriyama, Tomoyuki Yamashita, Yoshiyuki Tani, Tokuhiro Yamada, Akira Asada.   

Abstract

PURPOSE: We compared the negative chronotropic and inotropic effects of landiolol and esmolol, two clinically available short-acting beta1-blockers with high beta1-selectivity, using whole isolated rabbit heart preparations.
METHODS: Tachycardia was induced by continuous perfusion of 10(-7) M isoproterenol, and we used concentrations of landiolol or esmolol in ascending steps (1 . 10(-6), 3 . 10(-6), 1 . 10(-5), 3 . 10(-5), and 1 x 10(-4) M). Heart rate (HR), left ventricular developed pressure (LVDP), the maximal rates of left ventricular force development (LVdP/dt(max)), and myocardial oxygen consumption (MVO2) were measured and compared.
RESULTS: Both landiolol and esmolol produced dosedependent decreases in HR, LVDP, LVdP/dt(max), and MVO2. The HR lowering effects of the two agents were comparable. At concentrations of 3 . 10(-5) and 1 . 10(-4) M, esmolol produced more profound depression of LVDP (47 +/- 26 and 12 +/- 11 mmHg, respectively; mean +/- SD) and reduction of LVdP/dt(max) (650 +/- 287 and 120 +/- 103 mmHg x s(-1)) than landiolol (68 +/- 20 and 64 +/- 20 mmHg, and 897 +/- 236 and 852 +/- 240 mmHg.s(-1), respectively). At the same concentrations, esmolol caused more profound reduction in MVO(2) (40 +/- 11 and 35 +/- 10 microl x min(-1) x g(-1)) than landiolol (50 +/- 8 and 48 +/- 8 microl x min(-1) x g(-1)), respectively.
CONCLUSION: Our results indicate that in the isolated rabbit heart, landiolol and esmolol had equipotent negative chronotropic effects, however, landiolol had a less potent negative inotropic effect than esmolol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011773     DOI: 10.1007/s00540-008-0640-4

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  24 in total

1.  Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101.

Authors:  S Iguchi; H Iwamura; M Nishizaki; A Hayashi; K Senokuchi; K Kobayashi; K Sakaki; K Hachiya; Y Ichioka; M Kawamura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-06       Impact factor: 1.645

2.  The negative inotropic effect of esmolol on isolated cardiac muscle.

Authors:  P Arlock; B Wohlfart; T Sjöberg; S Steen
Journal:  Scand Cardiovasc J       Date:  2005-09       Impact factor: 1.589

3.  Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.

Authors:  K Muraki; H Nakagawa; N Nagano; S Henmi; H Kawasumi; T Nakanishi; K Imaizumi; T Tokuno; K Atsuki; Y Imaizumi; M Watanabe
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

4.  Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group.

Authors:  A Wallace; B Layug; I Tateo; J Li; M Hollenberg; W Browner; D Miller; D T Mangano
Journal:  Anesthesiology       Date:  1998-01       Impact factor: 7.892

5.  Beta-blockade versus Buckberg blood-cardioplegia in coronary bypass operation.

Authors:  F Kuhn-Régnier; E Natour; S Dhein; O Dapunt; H J Geissler; K LaRosé; C Görg; U Mehlhorn
Journal:  Eur J Cardiothorac Surg       Date:  1999-01       Impact factor: 4.191

6.  Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol.

Authors:  A Sugiyama; A Takahara; K Hashimoto
Journal:  J Cardiovasc Pharmacol       Date:  1999-07       Impact factor: 3.105

Review 7.  Peri-operative beta-blockade and haemodynamic optimisation in patients with coronary artery disease and decreasing exercise capacity presenting for major noncardiac surgery.

Authors:  B M Biccard
Journal:  Anaesthesia       Date:  2004-01       Impact factor: 6.955

8.  Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.

Authors:  J M Kirshenbaum; R A Kloner; E M Antman; E Braunwald
Journal:  Circulation       Date:  1985-10       Impact factor: 29.690

9.  Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts.

Authors:  Matthias L Riess; Leo G Kevin; Amadou K S Camara; James S Heisner; David F Stowe
Journal:  Anesthesiology       Date:  2004-03       Impact factor: 7.892

10.  Comparison of sarcoplasmic reticulum Ca2+-ATPase function in human, dog, rabbit, and mouse ventricular myocytes.

Authors:  Zhi Su; Fenghua Li; Kenneth W Spitzer; Atsushi Yao; Michael Ritter; William H Barry
Journal:  J Mol Cell Cardiol       Date:  2003-07       Impact factor: 5.000

View more
  16 in total

1.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

2.  Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia.

Authors:  Kensuke Nakamura; Ryota Inokuchi; Takahiro Hiruma; Kurato Tokunaga; Kent Doi; Susumu Nakajima
Journal:  J Anesth       Date:  2016-06-04       Impact factor: 2.078

Review 3.  Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

4.  Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis.

Authors:  Masaki Okajima; Masayuki Takamura; Takumi Taniguchi
Journal:  World J Crit Care Med       Date:  2015-08-04

5.  Very-low-dose continuous drip infusion of landiolol hydrochloride for postoperative atrial tachyarrhythmia in patients with poor left ventricular function.

Authors:  Akimasa Morisaki; Mitsuharu Hosono; Yasuyuki Sasaki; Hidekazu Hirai; Masanori Sakaguchi; Atsushi Nakahira; Hiroyuki Seo; Shigefumi Suehiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-05-08

6.  Successful management of a patient with Marfan syndrome complicated with acute aortic dissection using landiolol during Cesarean section.

Authors:  Noboru Saeki; Shima Taguchi; Masashi Kawamoto
Journal:  J Anesth       Date:  2010-01-26       Impact factor: 2.078

7.  Landiolol, an ultra short acting beta1-blocker, improves pulmonary edema after cardiopulmonary resuscitation with epinephrine in rats.

Authors:  Masahiro Uraoka; Yoshiki Nakajima; Tadayoshi Kurita; Akira Suzuki; Kotaro Takata; Shigehito Sato
Journal:  J Anesth       Date:  2009-12-29       Impact factor: 2.078

8.  A low-dose β1-blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the sarcoplasmic reticulum.

Authors:  Shigeki Kobayashi; Takehisa Susa; Hironori Ishiguchi; Takeki Myoren; Wakako Murakami; Takayoshi Kato; Masakazu Fukuda; Akihiro Hino; Takeshi Suetomi; Makoto Ono; Hitoshi Uchinoumi; Hiroki Tateishi; Mamoru Mochizuki; Tetsuro Oda; Shinichi Okuda; Masahiro Doi; Takeshi Yamamoto; Masafumi Yano
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

9.  Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction.

Authors:  Yuko Wada; Takeshi Aiba; Yasuyuki Tsujita; Hideki Itoh; Mitsuru Wada; Ikutaro Nakajima; Kohei Ishibashi; Hideo Okamura; Koji Miyamoto; Takashi Noda; Yasuo Sugano; Hideaki Kanzaki; Toshihisa Anzai; Kengo Kusano; Satoshi Yasuda; Minoru Horie; Hisao Ogawa
Journal:  J Arrhythm       Date:  2015-11-02

10.  Exploratory studies of some Mexican medicinal plants: Cardiovascular effects in rats with and without hypertension.

Authors:  Gil Alfonso Magos-Guerrero; Jacinto Santiago-Mejía; Omar F Carrasco
Journal:  J Intercult Ethnopharmacol       Date:  2017-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.